Urogen Pharma (NASDAQ:URGN – Get Free Report) and Assembly Biosciences (NASDAQ:ASMB – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.
Profitability
This table compares Urogen Pharma and Assembly Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Urogen Pharma | -51.73% | N/A | -43.79% |
| Assembly Biosciences | -0.06% | -0.02% | -0.02% |
Institutional and Insider Ownership
91.3% of Urogen Pharma shares are held by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are held by institutional investors. 4.8% of Urogen Pharma shares are held by insiders. Comparatively, 3.5% of Assembly Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Volatility and Risk
Analyst Ratings
This is a summary of current ratings and target prices for Urogen Pharma and Assembly Biosciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Urogen Pharma | 1 | 1 | 7 | 1 | 2.80 |
| Assembly Biosciences | 1 | 0 | 6 | 1 | 2.88 |
Urogen Pharma presently has a consensus price target of $50.38, indicating a potential upside of 14.25%. Assembly Biosciences has a consensus price target of $45.60, indicating a potential upside of 24.59%. Given Assembly Biosciences’ stronger consensus rating and higher probable upside, analysts clearly believe Assembly Biosciences is more favorable than Urogen Pharma.
Earnings and Valuation
This table compares Urogen Pharma and Assembly Biosciences”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Urogen Pharma | $109.79 million | 19.63 | -$153.49 million | ($1.98) | -22.27 |
| Assembly Biosciences | $72.30 million | 10.31 | -$6.12 million | $1.02 | 35.88 |
Assembly Biosciences has lower revenue, but higher earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.
About Urogen Pharma
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
About Assembly Biosciences
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
